Faced With Paying For Pricey Gene-Therapy Treatments, Insurers Start Thinking Outside The Box

The expensive new therapies can be life-changing, but working out how to pay for them has become a pain point for the health industry. “Employers are saying, ‘I just can’t afford it,’” said CVS Health Chief Medical Officer Troy Brennan. In other pharmaceutical news: drugmakers' try to gain traction for next-generation sequencing but the going is slow; and Pfizer gets fast-track approval for a rare lung caner drug.

from Kaiser Health News https://ift.tt/2UyiI3w